Recent Developments in Recombinant Protein–Based Dengue Vaccines
Recombinant proteins are gaining enormous importance these days due to their wide application as biopharmaceutical products and proven safety record. Various recombinant proteins of therapeutic and prophylactic importance have been successfully produced in microbial and higher expression host system...
Main Authors: | Nagesh K. Tripathi, Ambuj Shrivastava |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-08-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2018.01919/full |
Similar Items
-
Clinical development update: 1st dengue vaccine candidate
by: Alain Bouckenooghe
Published: (2016-02-01) -
Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults
by: Judith Kirstein, et al.
Published: (2018-09-01) -
Tetravalent dengue DNA vaccine is not immunogenic when delivered by retrograde infusion into salivary glands
by: Guy El Helou, et al.
Published: (2020-06-01) -
A new tetravalent Dengue vaccine formulation based on four chimeric envelope domain III-capsid proteins induces a functional immune response in mice and non-human primates
by: Edith Suzarte, et al. -
The Relevance of Tetravalent Influenza Vaccines. World experience
by: A. D. M. E. Osterhaus
Published: (2018-09-01)